Register by April 1 and Save up to $200!
Wednesday, April 27
8:30 am Chairperson’s Remarks
Samuel So, MBBS, FACS, Lui Hac Minh Professor, Surgery; Director, Asian Liver Center, Stanford University School of Medicine; Director, Liver Cancer Program, Stanford Cancer Center
8:35 Microbe Hunting
W. Ian Lipkin, M.D., Center for Infection and Immunity, Mailman School of Public Health, Columbia University
In this lecture, I will discuss mechanisms of microbial pathogenesis, routes to proving causation, and a staged strategy for surveillance and discovery. In reviewing the strengths and limitations of various analytical platforms, I will provide examples that illustrate how each platform can be used to investigate clinical problems.
9:05 Jaagsiekte Sheep Retrovirus and Lung Cancer
Hung Y. Fan, Ph.D., Professor, Molecular Biology and Biochemistry, Cancer Research Institute, University of California, Irvine
Jaagsiekte sheep retrovirus causes a transmissible lung cancer in sheep, ovine pulmonary carcinoma (OPA). OPA is an excellent model for human lung adenocarcinoma, and the mechanisms of viral oncogenesis may provide insights into human lung cancer. The possibility that human lung cancer may have a viral etiology will also be considered.
9:35 Chronic Viral Hepatitis and Liver Cancer - Untold Story of a Silent Epidemic
Samuel So, MBBS, FACS, Lui Hac Minh Professor, Surgery; Director, Asian Liver Center, Stanford University School of Medicine; Director, Liver Cancer Program, Stanford Cancer Center
Less well known than HIV, the hepatitis B and C virus have chronically infected half a billion people worldwide and put them at risk for primary hepatocelluar carcinoma, the third most common cause of cancer death in the world. Dr. So, who is a contributor to the Institute of Medicine report will discuss how overcoming ignorance and indifference is crucial to reverse the current tepid pace of prevention and treatment of chronic Hepatitis B and C, and to garner research resources to develop more effective liver cancer screening tests and treatments. If we don’t act now, millions of people worldwide will die in the next 10 years.
10:05 Refreshment Break, Poster Session & Exhibit Viewing
10:45 Chairperson’s Remarks
Wayne W. Grody, M.D., Ph.D., Professor, Divisions of Medical Genetics and Molecular Pathology, Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, UCLA School of Medicine
10:50 Nanotheragnostics: Stimuli-Triggered, Combined, and Multimodal Optical Imaging and Therapy for Cancer
Young Jik Kwon, Ph.D., Assistant Professor, Pharmaceutical Sciences, Chemical Engineering and Materials Science, University of California, Irvine
Identifying dysplasia with pinpointed accuracy and simultaneously potentiating therapeutics to act, only upon generating multiple diagnostic signals, are a new paradigm in combating against cancer. Novel polymer/inorganic hybrid nanomaterials that respond to molecular stimuli in early stage cancer for combined diagnosis, therapy, and prognosis (nanotheragnostics) will be presented.
11:20 Translating Biomarker Discovery into Clinical Validation for Early Cancer Detection: The Early Detection Research Network Experience in GI
Dean E. Brenner, M.D., Kutsche Family Professor of Internal Medicine; Professor, Pharmacology, Hematology/Oncology Division, University of Michigan Medical School
Biomarker discovery encompasses a multitude of technological approaches that incorporate high throughput technologies and mechanism driven, pathway based research. The Early Detection Research Network has developed research paradigms to rigorously screen and validate biomarkers for the early detection of cancers. We demonstrate the development of such approach using human research sets and the design and implementation of cross section validation projects using biomarkers for the early detection of colorectal cancer as an example.
11:50 Sponsored Presentation (Opportunity Available)
Sponsored by
12:20 Luncheon Presentation
Mode of Action Study of an Anticancer Agent by Metabolite Profiling
Hajo Schiewe, Ph.D., Senior Manager, Business Development, Metanomics Health at BASF
Metabolite profiling (metabolomics) enables the measurement of a wide range of metabolites, including unknown compounds and novel small molecules. Metabolite profiling data, generated through use of innovative bioinformatics and data mining tools and integrated with other data is the basis for system wide interpretation of complex biological functions, responses or regulations. As part of a study with a pharmaceutical partner two human adenocarcinoma cell lines (HCT116 – colon cancer and Du145 – prostate cancer) were both treated with an anticancer drug. Cell lysates were collected after 1.5h, 6h, and 24h of treatment and analyzed by two different metabolomics technologies with the goal to determine the mode of action of the anticancer drug.
1:30 Chairperson’s Remarks
Michael Liebman, Ph.D., President and Managing Director, Strategic Medicine, Inc.
1:35 AML: Novel Insights into Disease Biology and Therapy
Gary Schiller, M.D., F.A.C.P., Professor, Director, Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine, UCLA
How knowledge of pathophysiology informs drug development and clinical trials in Acute Myelogenous Leukemia. This session will focus on some of the regulatory challenges in drug development, concepts of unmet medical need, and the structure of clinical studies of new agents in the management of AML.
2:05 A Practical Model to Enhance Understanding of Tumors in Pharma
Sándor Szalma, Ph.D., Senior Research Fellow & Head, Oncology Informatics, Centocor R&D Inc.
In this talk I will show through some practical examples what strategies large pharma employs to develop deeper understanding of diseases. A combination of various internal learning processes and approaches and pre-competitive collaborative efforts will be used as illustrations from the translational cancer research field.
2:35 Translational Medicine: Starting in the Clinic not in the Lab
Michael Liebman, Ph.D., President and Managing Director, Strategic Medicine, Inc.
2:50 Panel Discussion: The Real Clinical Situation and Gaps that Remain between the Drug and the Clinical Need
Moderator: Michael Liebman, Ph.D., President and Managing Director, Strategic Medicine, Inc.
Panelists:
Gary Schiller, M.D., F.A.C.P., Professor, Director, Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine, UCLA
Sándor Szalma, Ph.D., Senior Research Fellow & Head, Oncology Informatics, Centocor R&D Inc.
3:05 Refreshment Break, Poster Session & Exhibit Viewing-Complimentary Access for UC Irvine Affiliates
3:45 Panel Discussion: Biomarkers in Translational Cancer Research: Realities of Translation
Moderator: Frank L. Meyskens, Jr., M.D., Director, Chao Family Cancer Center, University of California, Irvine
Panelists:
Dean E. Brenner, M.D., Kutsche Family Professor of Internal Medicine; Professor, Pharmacology, Hematology/Oncology Division, University of Michigan Medical School
James H. Doroshow, M.D., Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute
Gregory J. Riggins, M.D., Ph.D., Professor of Neurosurgery & Oncology, Director, Division of Neurosurgery Research, Ludwig Collaborative Laboratory for Cancer Biology and Therapy, Johns Hopkins University
4:45 Conference Wrap-Up and Closing Remarks
Gregory A. Weiss, Ph.D., Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
5:00 Close of Conference